Skip to Content
MilliporeSigma
  • Epigallocatechin gallate attenuates ET-1-induced contraction in carotid artery from type 2 diabetic OLETF rat at chronic stage of disease.

Epigallocatechin gallate attenuates ET-1-induced contraction in carotid artery from type 2 diabetic OLETF rat at chronic stage of disease.

Life sciences (2013-12-03)
Takayuki Matsumoto, Shun Watanabe, Ryusuke Kawamura, Kumiko Taguchi, Tsuneo Kobayashi
ABSTRACT

There is a growing body of evidence suggesting that epigallocatechin gallate (EGCG), a major catechin isolated from green tea, has several beneficial effects, such as anti-oxidant and anti-inflammatory activities. However, whether treatment with EGCG can suppress the endothelin-1 (ET-1)-induced contraction in carotid arteries from type 2 diabetic rats is unknown, especially at the chronic stage of the disease. We hypothesized that long-term treatment with EGCG would attenuate ET-1-induced contractions in type 2 diabetic arteries. Otsuka Long-Evans Tokushima fatty (OLETF) rats (43 weeks old) were treated with EGCG (200 mg/kg/day for 2 months, p.o.), and the responsiveness to ET-1, phenylephrine (PE), acetylcholine (ACh) and sodium nitroprusside (SNP) was measured in common carotid artery (CA) from EGCG-treated and -untreated OLETF rats and control Long-Evans Tokushima Otsuka (LETO) rats. In OLETF rats, EGCG attenuated responsiveness to ET-1 in CA compared to untreated groups. However, EGCG did not alter PE-induced contractions in CA from OLETF rats. In endothelium-denuded arteries, EGCG did not affect ET-1-induced contractions in either the OLETF or LETO group. Acetylcholine-induced relaxation was increased by EGCG treatment in CA from the OLETF group. The expressions of ET receptors, endothelial nitric oxide synthase, superoxide dismutases, and gp91(phox) [an NAD(P)H oxidase component] in CA were not altered by EGCG treatment in either group. Our data suggest that, within the timescale investigated here, EGCG attenuates ET-1-induced contractions in CA from type 2 diabetic rats, and one of the mechanisms may involve normalizing endothelial function.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethanolamine, ACS reagent, ≥99.0%
Sigma-Aldrich
Ethanolamine, purified by redistillation, ≥99.5%
Sigma-Aldrich
Ethanolamine, ≥99%
Supelco
Aucubin, analytical standard
Supelco
Ethanolamine, analytical standard
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Ethanolamine, puriss. p.a., ACS reagent, ≥99.0% (GC/NT)
Sigma-Aldrich
Cholesterol, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
Ethanolamine, liquid, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
Ethanolamine, ≥98%
Sigma-Aldrich
Cholesterol, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
Sigma-Aldrich
Acetylcholine bromide, ≥99%
Sigma-Aldrich
Endothelin 1, ≥97% (HPLC), powder
Sigma-Aldrich
Ethanolamine, JIS special grade, ≥99.0%
Sigma-Aldrich
Ethanolamine, SAJ first grade, ≥99.0%
Sigma-Aldrich
3-[(1R)-1-Hydroxy-2-(methylamino)ethyl]phenol, AldrichCPR
Aucubin, primary reference standard
Supelco
Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material
SAFC
Cholesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
Acetylcholine chloride, pkg of 150 mg (per vial)
SAFC
Cholesterol, Plant-Derived, SyntheChol®
Sigma-Aldrich
Sodium deoxycholate, BioXtra, ≥98.0% (dry matter, NT)
Sigma-Aldrich
Acetylcholine chloride, ≥99% (TLC)
Sigma-Aldrich
Acetylcholine chloride, suitable for cell culture
Sigma-Aldrich
Sodium deoxycholate, ≥97% (titration)
Supelco
Sodium Nitroprusside, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetylcholine chloride, ≥99% (TLC), free-flowing, Redi-Dri
Phenylephrine, European Pharmacopoeia (EP) Reference Standard